Quantcast

Industry news that matters to you.  Learn more

Archives for October 2010

Area Biotech Company Banyan Biomarkers On Cutting Edge

The founders of Banyan Biomarkers describe the Alachua-based research firm as a “Gator-made company.”

Banyan made news recently when it was awarded a $26.3 million Department of Defense contract to develop a diagnostic blood test for traumatic brain injury, or TBI. The company has been studying “biomarkers,” or proteins in the blood produced by an injured brain.

Compendia Bioscience Morphs Into Big Pharma’s Cancer Genomics Partner

Compendia Bioscience has evolved significantly since it spun out of the University of Michigan with its cancer genomics research software four years ago. Instead of just selling software and moving on to the next customer, Compendia co-founder and CEO, Daniel Rhodes, says that his firm has prospered by forming close ties to pharmaceutical companies that rely on the firm’s expertise and technology.

“We’re transforming from a software company only to really a collaboration partner with pharma, where we are licensing them access to our technology but also providing expertise and services,” Rhodes says. “So it’s a really exciting time for our company right now.”

Revalesio Partners with Predictive Biomarker Sciences to Assess Potential Cancer Treatment

Revalesio Corporation announced today that it has contracted with Predictive Biomarker Sciences (PBS-Bio) to conduct studies related to the use of Revalesio’s novel anti-inflammatory therapeutic in treating cancer.

To jump-start drug development, PBS-Bio’s analysis helps pharmaceutical companies better understand how their drugs work and identifies biomarkers that can help predict which patients will respond to treatment.

Caprion Proteomics Identifies Promising New Candidate Biomarkers to Predict Response to Hepatitis C Treatment

Caprion Proteomics announced today that it has identified promising candidate protein biomarker panels that appear to predict patient responsiveness to treatment for hepatitis C.

The study employed Caprion’s proprietary CellCarta mass spectrometry-based proteomics discovery platform to measure and compare the expression levels of thousands of proteins contained in blood samples collected from patients infected with the hepatitis C virus (HCV), in order to discover predictive biomarkers of sustained response to hepatitis C therapy.

UK launches Stratified Medicines Innovation Platform

The UK’s Technology Strategy Board has launched a new programme designed to place the country at the forefront of medicines tailored to smaller and more responsive subsets of patients.

The Stratified Medicines Innovation Platform will bring together researchers, policymakers and the private sector in an initiative drawing on government funding of over £50 million for innovative research and development in areas such as tumour profiling to improve cancer care and biomarker development to enhance drug effectiveness.